Elderberries and Obesity

February 8, 2023 updated by: Patrick Solverson, Washington State University

Supporting Local Agriculture Via Clinical Research: Human Studies With Elderberries to Improve Biomarkers of Obesity

Previous studies in humans indicate that anthocyanin-rich berries can positively alter fat oxidation and insulin sensitivity. This study will determine if this is also true with elderberries, which are a more concentrated source of anthocyanins compared to other commonly consumed berries.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Washington
      • Spokane, Washington, United States, 99202
        • Nutrition and Exercise Physiology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Women and Men between 22 and 75 years of age with a body mass index of 25 kg/m2 or above.

Exclusion Criteria:

  • Are not fully vaccinated against COVID-19 (at least 2-weeks out from final dose at time of staff meeting)
  • Have a body mass index less than 25 kg/m2
  • Are younger than 22 years of age, or older than 75 years of age
  • Pregnant, lactating, or intending to become pregnant during the study period, or have given birth in the past year
  • Known allergy or intolerance to elderberries
  • History of bariatric surgery or nutrient malabsorption disease (such as celiac disease) or other metabolic disorders requiring a special diet that is not in accord with the diet behavior requested for this study
  • Adherence to restrictive (vegetarian or vegan) or extreme (fad [ex. Ketogenic or Atkins] or quick weight loss/gain) diet patterns and unwillingness to consume a conventional, omnivorous diet and maintain body weight
  • Habitual use of tobacco or marijuana (including vaping) products in the last 6 months
  • Diagnosis or treatment of cancer in the past 3 years
  • Crohn's disease or diverticulitis
  • Suspected or known strictures, fistulas or physiological/mechanical GI obstruction
  • Use of certain medications (prescription or over-the-counter) that may interfere with the study objectives, including blood thinning medications
  • Type 2 diabetes requiring the use of medication
  • Fasting blood glucose > 125 mg/dL
  • Unable or unwilling to give informed consent or communicate with study staff
  • Self-report of alcohol or substance abuse within the past 12 months and/or current treatment for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)
  • Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Elderberry juice
Participants will consume elderberry juice twice/day for 1-week.
Participants will consume elderberry juice 1-week.
PLACEBO_COMPARATOR: Placebo beverage
Participants will consume placebo beverage twice/day for 1-week.
Participants will consume placebo for 1-week.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Substrate oxidation
Time Frame: 3.5 hours
Participants will be monitored by a metabolic cart at rest and while walking
3.5 hours
Glucose tolerance/insulin sensitivity
Time Frame: 3 hours
Blood will be collected following a meal tolerance test
3 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 27, 2021

Primary Completion (ACTUAL)

September 2, 2022

Study Completion (ACTUAL)

September 2, 2022

Study Registration Dates

First Submitted

July 20, 2021

First Submitted That Met QC Criteria

February 8, 2023

First Posted (ACTUAL)

February 10, 2023

Study Record Updates

Last Update Posted (ACTUAL)

February 10, 2023

Last Update Submitted That Met QC Criteria

February 8, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 18682

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fuel Management

Clinical Trials on Elderberry juice

Search Similar Trials